Highest-materiality recent filing
Spero posts Q1 net loss of $7.2M; tebipenem HBr PDUFA date June 18, 2026
Net loss of $7.2M ($0.13 diluted EPS) vs $13.9M loss ($0.25 EPS) in Q1 2025.
Spero posts Q4 net income $31.5M; tebipenem HBr PDUFA set for June 18, 2026
Q4 2025 net income $31.5M (vs $20.9M loss); diluted EPS $0.53.
Director resigns; SEC concludes investigation with no enforcement action
Ankit Mahadevia, MD resigned from board effective Jan 30, 2026 due to other professional commitments; no dispute with company.
GSK files NDA resubmission for tebipenem HBr; Spero to receive $25M milestone in Q1 2026
GSK resubmitted NDA to FDA for oral carbapenem tebipenem HBr for cUTI/pyelonephritis.
Spero Therapeutics Q3 net loss narrows to $7.4M; GSK plans FDA filing for tebipenem HBr in Q4 2025
Net loss of $7.4M ($0.13 EPS) vs $17.1M ($0.32 EPS) in Q3 2024; revenue $5.4M, down from $13.5M.
Spero reports Q2 results and tebipenem Phase 3 success; plans FDA filing in 2H 2025
Q2 2025 net loss $1.7M ($0.03/share) vs $17.9M ($0.33) in Q2 2024; revenue $14.2M up from $10.2M.
Stockholders approved amendment to 2017 Plan increasing authorized shares by 3,000,000.
Spero/GSK Phase 3 PIVOT-PO trial for tebipenem HBr meets primary endpoint, stops early for efficacy
Tebipenem HBr met non-inferiority vs IV imipenem-cilastatin in 1,690 cUTI patients; IDMC recommended early stop.
Spero Q1 loss $13.9M, revenue $5.9M; appoints new CEO, tebipenem trial interim on track
Net loss $13.9M ($0.25/share) vs $12.7M loss in Q1 2024; revenue $5.9M down from $9.3M.
Esther Rajavelu named Spero CEO effective May 2; former CEO Sath Shukla departs
Esther Rajavelu appointed President and CEO effective May 2, 2025; nominated for board election at annual meeting.
Spero posts Q4 net loss of $20.9M; revenue down 80% YoY; pipeline setbacks and SEC Wells Notice
Net loss of $20.9M in Q4 2024 vs net income of $51.2M in Q4 2023; diluted EPS loss of $(0.38).
Nasdaq notified Spero on Feb 25, 2025 that its stock closed below $1.00 for 30 consecutive trading days.
Spero Therapeutics receives SEC Wells Notice; CEO placed on paid administrative leave
SEC staff preliminarily recommends enforcement action over 2022 disclosures on tebipenem HBr commercialization.
Spero Q3 net loss widens to $17.1M; SPR720 halted after Phase 2a miss
Q3 net loss of $17.1M ($0.32 EPS) vs $3.2M loss a year ago; revenue fell 47% to $13.5M.
SPR720 Phase 2a interim analysis did not meet primary endpoint; 3 cases of reversible grade 3 hepatotoxicity at 1,000 mg dose.
Filed an updated investor presentation dated September 9, 2024, under Regulation FD.
Spero Therapeutics Q2 net loss $17.9M; CMO departs; SPR720 data expected 4Q 2024
Net loss $17.9M ($0.33/share) vs $11.9M loss ($0.23) in Q2 2023; revenue $10.2M up from $2.7M.
Spero Therapeutics shareholders approve 3M share increase for 2017 stock plan
Stockholders approved amendment to 2017 Stock Incentive Plan, adding 3,000,000 authorized shares.
Spero Therapeutics Q1 net loss $12.7M; SPR720 Phase 2a data expected 2H 2024
Net loss $12.7M ($0.24/share) vs $13.3M ($0.25/share) in Q1 2023; revenue $9.3M up from $2.1M.
Spero Therapeutics sets 2024 Annual Meeting for May 29, 2024 (online)
Annual Meeting on May 29, 2024, will be held entirely online via virtual format.
Spero Therapeutics reports Q4 2023 net income of $51.2M; SPR720 topline data expected 2H 2024
Q4 2023 net income of $51.2M ($0.96 diluted EPS) vs $26.8M in Q4 2022; full-year net income of $22.8M ($0.43 diluted EPS).
On April 28, 2025, Spero Therapeutics, Inc. (the “Company”) announced that effective as of May 2, 2025 (the “Effective Date”), Esther Rajavelu will serve as the Company’s President and Chief Executive Officer.
Max materiality 0.90 · Median 0.70 · Most common event earnings